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Purpose: To estimate the efficacy of third-generation (3G) chemo-
therapy agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, and
irinotecan) on response and survival in stage IIIB/IV non-small cell
lung cancer (NSCLC).
Methods: A meta-analysis was performed using trials identified
through MEDLINE. Results on tumor response and survival were
collected from randomized trials comparing 3G monotherapy versus
best supportive care (BSC), 3G monotherapy versus second-gener-
ation (2G) platinum-based regimens, and 3G platinum-based regi-
mens versus 2G platinum-based regimens.
Results: Of the 2480 citations screened, 20 randomized controlled
trials fulfilled the inclusion and exclusion criteria, and 19 trials were
used in the analyses. The data from two, three-arm trials were used
in two different comparisons. Five trials (n  1029 patients) com-
pared 3G monotherapy with BSC. The summary risk difference
(RD) for 1-year survival favored 3G agents by 7% (95% confidence
interval [CI]: 2%, 12%). Four trials (n  871 patients) compared
treatment with 3G monotherapy versus 2G platinum-based regi-
mens. The response RD was 6% (95% CI: 11%, 0%), and the
1-year survival rate RD was 3% (95% CI: 3%, 10%), suggesting
that despite a slightly higher response rate for 2G platinum-based
regimens relative to 3G monotherapy, there is equivalency in sur-
vival. Twelve trials (n  3995) compared 3G versus 2G platinum-
based regimens. The RD for response was 12% (95% CI: 10%,
15%). A RD for 1-year was not calculated, because of heterogeneity
among the trials. A subset analysis of 3G versus 2G platinum-based
doublets revealed a 1-year survival-rate RD of 6% (95% CI: 2%,
10%), favoring 3G platinum-based regimens without evidence of
heterogeneity.
Conclusions: 3G agents have been a significant advance in the
treatment of NSCLC.
Key Words: Paclitaxel, Docetaxel, Gemcitabine, Vinorelbine,
Irinotecan.
(J Thorac Oncol. 2007;2: 845–853)
Lung cancer remains the leading cause of cancer-relatedmortality among men and women, and in 2007 in the
United States more patients will die of lung cancer than of
breast, colon, and prostate cancers combined.1 It is estimated
that in the United States in 2007, there will be approximately
213,000 new diagnoses of lung cancer, and 160,000 deaths
resulting from lung cancer.1 Approximately 85% of these
cases were non-small cell lung cancer (NSCLC), and two
thirds of these patients were stage IIIB or IV at the time of
diagnosis.2–4 For patients with preserved functional status,
the current standard of care is double-agent platinum-based
chemotherapy.5 The median survival and 1-year survival
rates with platinum-based therapy are 8 to 10 months and
30% to 35%, respectively.6
During the 1990s, new agents including paclitaxel, do-
cetaxel, gemcitabine, vinorelbine, and irinotecan emerged as
active single agents in stage IIIB/IV NSCLC. These agents have
been termed third-generation (3G) agents and have single-agent
response rates of 10% to 20%.7–12 The 3G agents were rapidly
adopted in the treatment in advanced NSCLC, although ques-
tions remain about their efficacy relative to the previous standard
therapies, often referred to as 2G agents or regimens. These
regimens include cisplatin alone or in combination with older
agents such as etoposide, vindesine, mitomycin, or ifosfamide.
Numerous trials have evaluated 3G agents alone or in combina-
tion with other agents. Nevertheless, disparate trial designs and
comparator arms have been employed, and many trials have not
been adequately powered to determine the superiority of one
treatment over others.
To determine whether there is an increase in efficacy of
the 3G agents, as measured by response and 1-year survival
rate, we performed a meta-analysis of randomized trials. A
meta-analysis may provide sufficient power to detect statis-
tically and clinically relevant differences in the efficacy of 3G
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agents in comparison with previous therapies. Meta-analyses
can be performed using data extracted from the published
literature or individual patient data. The use of individual
patient data is less likely to overestimate the treatment effect
and is more valuable when times to event outcomes are being
evaluated.13 The availability of individual patient data facil-
itates investigations into the relationships between patient
characteristics and treatment and impact on heterogeneity.
The use of a definitive endpoint, such as 1-year survival rate,
reduces the variability in reporting of the efficacy parameter
and the dependency on individual patient data. In addition to
detecting clinically relevant differences between treatments,
we attempted to quantify the difference between the two
treatments. The risk difference (RD) and the number needed
to treat (NNT) were calculated to estimate the benefit of
treatment with 3G agents.
METHODS
Literature Search
Potentially eligible studies were identified using a
MEDLINE search for the period of January 1980 to March
2004. Search terms included the following combined subject
headings: paclitaxel, docetaxel, gemcitabine, vinorelbine, iri-
notecan, lung neoplasms, randomization, and clinical trial.
The bibliographies of retrieved randomized clinical trials,
meta-analyses, and narrative review articles were reviewed
by the authors. The pharmaceutical companies were con-
tacted to identify additional clinical trials involving their 3G
agents in NSCLC. The results of these searches were com-
bined to yield a common set of citations from which the titles
and abstracts were screened for potential qualifying studies.
A citation identified by any of the search strategies was
reviewed by all of the investigators. The decision to select
an article was based on information available in the pub-
lished report and was reached by consensus among the
study authors.
Inclusion Criteria
3G agents were defined as paclitaxel, docetaxel, gem-
citabine, vinorelbine, and irinotecan. 2G regimens were de-
fined as a platinum alone or platinum in combination with
older agents including etoposide, vindesine, ifosfamide, and
mitomycin. Studies were included only if they were random-
ized controlled trials published in peer-reviewed journals
between January 1980 and March 2004. All patients must
have been previously untreated and diagnosed with advanced
stage NSCLC. Treatment comparisons could be any one of
the following combinations: 3G monotherapy versus best
supportive care; 3G monotherapy versus 2G platinum-based
regimen; and 3G platinum-based versus 2G platinum-based
regimen. Abstracts were not included, because of issues with
incompleteness of the data and potential issues with the
quality of data abstracted from non–peer-reviewed sources.
Data Abstraction
The following data were abstracted directly from the
published trials: type and dosage of chemotherapy, number of
patients randomized to each arm of chemotherapy, gender,
age, race, performance status, stage, pathologic type, weight
FIGURE 1. Selection of trials.
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loss 5%, previous radiotherapy, schedule of systemic che-
motherapy, response (overall, complete, partial, stable dis-
ease, progression), and 1-year survival rate.
Data Analysis
Publication bias was assessed using funnel plots for
asymmetry and using the symmetry tests of Begg and Ma-
zumdar,14 and Sterne et al.15 These tests examine the associ-
ation between estimated treatment effects and the precision of
the estimates. The Begg and Mazumdar test uses an adjusted
rank correlation method, whereas the Sterne et al. test uses a
linear regression model. In addition, each group of studies
was examined for overall heterogeneity to ensure that syn-
thesis was warranted. The homogeneity p value was required
to be 0.1 for a summary RD to be presented. These
estimates were computed as inverse-variance weighted aver-
TABLE 1. Characteristics of Studies Included in the Meta-analysis, and Their Patient Populations
First Author or
Study Group Phase Therapy Therapy Class
Number of
Patients
Median
Age (yr)
Percent
Male
Percent
PS 0–1
KPS > 70%
Percent
Stage
IIIB
Percent
Stage
IV
Le Chevalier16 III Cisplatin, vinorelbine 3G platinum based 206 59 88 80 28 50
Vinorelbine 3G monotherapy 206 60 87 77 32 47
Cisplatin, vindesine 2G platinum based 200 59 90 82 25 55
Crawford7 — Vinorelbine 3G monotherapy 143 61 71 100 0 100
5FU/LCV BSC 68 61 71 100 0 100
Baldini20 — Carboplatin, vinorelbine 3G platinum based 43 61 88 88 33 67
Cisplatin, ifosfamide, vinorelbine 3G platinum based 48 64 88 87 38 63
Cisplatin, vindesine, mitomycin 2G platinum based 49 62 84 79 31 69
Giaccone21 II/III Cisplatin, paclitaxel 3G platinum based 155 59 71 87 37 63
Cisplatin, teniposide 2G platinum based 162 59 70 92 40 60
Wozniak22 III Cisplatin, vinorelbine 3G platinum based 206 63 68 100 8 92
Cisplatin 2G platinum based 209 63 67 100 8 92
Cardenal23 — Cisplatin, gemcitabine 3G platinum based 69 59 93 83 48 52
Cisplatin, etoposide 2G platinum based 66 58 92 88 52 49
Crino24 III Cisplatin, gemcitabine 3G platinum based 155 62 85 93 21 79
Cisplatin, mitomycin, ifosfamide 2G platinum based 152 60 84 95 21 79
ELVIS8 — Vinorelbine 3G monotherapy 76 74 86 76 27 73
BSC BSC 78 74 89 76 28 72
ten Bokkel Huinink17 II Gemcitabine 3G monotherapy 72 59 74 82 18 76
Cisplatin, etoposide 2G platinum based 75 59 81 91 17 75
Perng18 II Gemcitabine 3G monotherapy 27 63 67 89 30 67
Cisplatin, etoposide 2G platinum based 26 60 62 69 15 81
Anderson9 — Gemcitabine 3G monotherapy 150 65 66 30 59 41
BSC BSC 150 64 61 27 61 39
Bonomi25 III Cisplatin, high dose paclitaxel 3G platinum based 201 61 63 100 20 80
Cisplatin, low-dose paclitaxel 3G platinum based 198 63 62 100 23 77
Cisplatin, etoposide 2G platinum based 200 62 66 100 15 85
Gatzemeier26 III Cisplatin, paclitaxel 3G platinum based 207 60 80 82 30 70
Cisplatin 2G platinum based 207 60 81 81 30 70
Ranson10 III Paclitaxel 3G monotherapy 79 65 73 84 49 51
BSC BSC 78 64 76 82 41 59
Roszkowski11 III Docetaxel 3G monotherapy 137 59 80 81 56 44
BSC BSC 70 60 84 77 47 53
Sandler27 III Cisplatin, gemcitabine 3G platinum based 260 62 70 80 26 67
Cisplatin 2G platinum based 262 63 71 88 23 70
Gebbia28 III Cisplatin, vinorelbine 3G platinum based 122 61 72 76 55 45
Cisplatin, vindesine, mitomycin 2G platinum based 125 60 78 71 54 46
Negoro19 III Cisplatin, irinotecan 3G platinum based 129 64 76 94 38 62
Irinotecan 3G monotherapy 129 62 74 94 34 66
Cisplatin, vindesine 2G platinum based 122 64 80 94 38 62
Kubota29 III Cisplatin, docetaxel 3G platinum based 151 63 64 96 0 100
Cisplatin, vindesine 2G platinum based 151 64 68 97 0 100
BSC, best supportive care; 2G, second generation; 3G, third generation.
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ages of the estimates from the individual studies. When there
was little evidence of heterogeneity or publication bias,
summary estimates of the RD were presented. The RD (or
absolute risk reduction) is the actual difference in survival
rates between two comparison groups and is defined as 1 
2, where 1 and 2 are the proportions of patients in study
arms 1 and 2 that experience the endpoints of interest,
respectively. The NNT is defined as 1/(1  2) and repre-
sents the estimated number of patients that would need to be
treated on the more beneficial study arm to prevent one
adverse outcome. Survival at 1 year was based on intent to
treat, and response rates were based on the patients who were
assessable. Therefore, the number of patients in a survival
analysis may exceed the number in a response analysis. All
analyses were performed using the STATA statistical soft-
ware, release 7.0 (Stata Corp, College Station, TX).
RESULTS
Search of the Published Literature
Two thousand four hundred eighty citations were re-
viewed, and 20 clinical trials met the criteria set forth in the
methods section (Figure 1). Examination of review articles,
meta-analyses, and retrieved trials did not identify any addi-
tional randomized clinical trials appropriate for inclusion in
this analysis. One study was rejected because it compared a
3G agent against a 2G platinum-based regimen (epirubicin/
cisplatin) that is not commonly used for NSCLC.
Characteristics of Included Studies
A total of 19 studies with 5895 patients were included
in this meta-analysis (Table 1).The trials were divided into
three groups: (1) all randomized trials that compared 3G
agents as single agents to BSC (five trials, n 1029 patients),
(2) all randomized trials that evaluated 3G agents as mono-
therapy compared with 2G platinum-based combination reg-
imens (four trials, n  871 patients), and (3) all randomized
trials that compared 3G agents in combination with platinum-
based therapy compared with 2G regimens (12 trials, n 
3995 patients). All of the trials comparing 3G agents in
combination with platinum therapy against 2G regimens were
published in or after 1994.
Treatment Comparisons
Five trials (n  1029 patients) compared 3G single
agents with BSC (Table 2).7–11 Four of the trials included a
BSC control arm, and one trial included 5-fluorouracil (5FU)/
leucovorin as the control arm. This trial was included because
the 5-FU/leucovorin control arm had an overall response rate
of 3% and a survival profile similar to the BSC arms of the
other four trials. Response comparisons were not appropriate
for 3G single agents against BSC. Nevertheless, response
rates for the 3G agents ranged from 12% to 20%. Compari-
sons of 1-year survival rates demonstrated little evidence of
heterogeneity or publication bias (Table 3). One-year survival
favored the 3G agents over BSC (Figure 2), with a summary
RD of 7% (95% confidence interval [CI]: 2% to 12%), The
NNT for one patient to realize a benefit in the probability of
1-year survival was 14.
Four trials (n 871 patients) compared 3G mono-
therapy with 2G platinum-based combination regimens (Ta-
ble 4).16–19 These trials ranged in size from 53 to 406 patients.
TABLE 2. Third-Generation Single Agents Compared with Best Supportive Care
First Author or
Study Group Therapy
Number
of Patients
Patients
Assessable
Overall
Response Rate (%)
Survival
No. of
Patients
1-yr
Survival (%)
Crawford7 Vinorelbine 143 126 12 143 25
5FU/LCV 68 58 3 68 16
ELVIS8 Vinorelbine 76 70 20 76 32
BSC 78 — — 78 14
Anderson9 Gemcitabine 150 135 17 150 25
BSC 150 — — 150 22
Ranson10 Paclitaxel 79 76 16 79 24
BSC 78 — — 78 23
Roszkowski11 Docetaxel 137 92 20 137 25
BSC 70 — — 70 16
BSC, best supportive care.
TABLE 3. Homogeneity and Publication Test Results
Comparison
Homogeneity
p Value
Begg and
Mazumdar14
p Value
Sterne et al15
p Value
3G vs. BSC survival
Overall survival 0.4 1.0 0.7
Single-agent 3G vs.
2G platinum based
Response 0.5 0.5 0.7
Overall survival 0.3 0.5 0.3
3G platinum based vs.
2G platinum based
Response 0.2 0.3 0.1
Overall survival 0.1 0.2 0.3
3G, third generation; 2G, second generation; BSC, best supportive care.
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Two trials were three-arm trials, and the relevant data from
the 3G monotherapy and the 2G treatment arms were ex-
tracted from these trials.16,19 There was no evidence of
heterogeneity or publication bias (Table 3). The summary RD
estimate for response was 6% (95% CI: 11%, 0%), and
for 1-year survival rate was 3% (95% CI: 3%, 10%).
Despite a suggestion of greater response for the 2G regimens,
the RD for survival was close to the null value, suggesting that
there is no difference in efficacy between 3G monotherapy and
2G platinum-based combined regimens (Figure 3).
Twelve trials (n 3995 patients) compared 3G combi-
nation regimens including platinum-based compounds with
2G platinum-based regimens (Table 5).16,19–29 These trials
ranged in size from 92 to 572 patients. Two trials were
three-arm trials, and the relevant data related to 3G combi-
nation and 2G combination treatments were extracted.16,19
One trial compared a 2G combination against a 3G combi-
nation using two different doses of paclitaxel; for that trial,
the data from the two paclitaxel arms were combined.25 For
response, there was no evidence of heterogeneity or publica-
tion bias (Table 3). The estimated RD was 12% (95% CI:
10%, 15%), corresponding to an NNT of eight for one patient
to benefit (Figure 4). For 1-year survival (Figure 5), there was
a high degree of heterogeneity among the studies, as evi-
denced by the homogeneity p value of 0.10, which raises
concerns about the validity of combining data from these
trials.
DISCUSSION
This meta-analysis clearly demonstrates that 3G mono-
therapy improves 1-year survival in comparison with BSC. It
should be noted that one of these trials, the Elderly Lung
FIGURE 2. Third-generation agents compared with best
supportive care. Differences in 1-year survival proportions.
FIGURE 3. Third-generation single agents compared with
second-generation platinum-based regimens. Differences in
response and 1-year survival proportions.
TABLE 4. Third-Generation Single Agents Compared with Second-Generation Platinum-Based
Regimens
First Author Therapy
Number
of Patients
Patients
Assessable
Overall
Response Rate (%)
Survival
No. of
Patients
1-yr
Survival (%)
Le Chevalier*16 Vinorelbine 206 199 14 206 30
Cisplatin, vindesine 200 183 19 200 27
ten Bokkel Huinink17 Gemcitabine 72a 59 20 67b 25
Cisplatin, etoposide 75a 62 18 72b 24
Perng18 Gemcitabine 27 26 19 27 41
Cisplatin, etoposide 26 24 21 26 31
Negoro*19 Irinotecan 132 127 20 129 42
Cisplatin, vindesine 133 120 32 122 38
a Patients randomized; b patients eligible after randomization. *The relevant data from two three-arm trials were extracted and used in
the comparison of 3G monotherapy versus 2G platinum-based therapy. Data are not shown for the treatment arm of cisplatin/vinorelbine in
the trial by Le Chevalier et al.16 or for the treatment arm of cisplatin/irinotecan in the trial by Negoro et al.19
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Cancer Vinorelbine Italian Study,8 consisted of patients age
70 years, and nearly a quarter of the patients had a perfor-
mance status of 2. Treatment with vinorelbine was superior to
BSC on this trial; nevertheless, the data on the efficacy of
single-agent vinorelbine may be underestimated because of
the patient selection on the trial. The inclusion of the data
from 5-FU/leucovorin (LCV) arm as best supportive care
from the trial by Crawford et al.7 may be debatable. Neverthe-
less, the response and survival on that arm were similar to the
BSC arm on other trials, and 5-FU/leucovorin is not considered
an active or standard therapy for advanced NSCLC; thus, we
feel the inclusion of this trial was justifiable.
Other meta-analyses of older agents have revealed a
survival benefit of chemotherapy over BSC.30,31 Whereas
response is undefined in supportive care, response rates for
the 3G single agents ranged from 13% to 20%, which is
consistent with a recent meta-analysis that have found the
response rates of single-agent chemotherapy to be 13%.32 A
systematic review by Sorenson et al.33 of chemotherapy in
advanced NSCLC has revealed that treatment with single-
agent paclitaxel, docetaxel, or vinorelbine provided a survival
benefit over BSC comparable with older, cisplatin-based
combinations.
Our analysis suggests that treatment with 3G mono-
therapy compared with 2G platinum-based combination ther-
apies yields similar 1-year survival, despite a slightly lower
response rate with 3G monotherapy. 3G monotherapy may
actually be preferable to 2G combination regimens, because
single-agent therapy generally has a lower rate of grade 3 and
4 toxicity than double-agent therapy.32 A meta-analysis by
Lilenbaum et al.34 investigated the effects of single-agent
versus combination chemotherapy on response rate, toxicity,
and survival. This meta-analysis found superior response rate
and a modest improvement in the 6-month and 1-year sur-
vival rates with combination therapy. Nevertheless, when a
platinum agent or vinorelbine was used as a single agent, the
differences in 6-month and 1-year survival were no longer
significant. Combination therapy was associated with a 3.6-
fold increase in the risk of treatment-related death, and
significantly greater toxicity.
The inclusion of single-agent cisplatin as a 2G regimen
may be debatable; nevertheless, single-agent cisplatin was
TABLE 5. Third-Generation Platinum-Based Regimens Compared with Second-Generation Platinum-Based
Regimens
First Author Therapy
Number
of Patients
Patients
Assessable
Overall
Response Rate (%)
Survival
No. of
Patients
1-yr
Survival (%)
Le Chevalier*16 Cisplatin, vinorelbine 206 192 30 206 34
Cisplatin, vindesine 200 183 19 200 27
Baldini20 Carboplatin, vinorelbine 43 43 14 43 16
Cisplatin, vindesine, mitomycin 49 49 14 49 18
Giaccone21 Cisplatin, paclitaxel 155b 141 45 166a 41
Cisplatin, teniposide 162b 141 32 166a 40
Wozniak22 Cisplatin, vinorelbine 209 206 26 206 36
Cisplatin 206 209 12 209 20
Cardenal23 Cisplatin, gemcitabine 69 69 41 69 32
Cisplatin, etoposide 64b 64 22 64 27
Crino24 Cisplatin, gemcitabine 155 155 38 155 33
Cisplatin, mitomycin, ifosfamide 152 152 26 152 34
Bonomi25 Cisplatin, high-dose paclitaxel 191 381 27 381 39c
Cisplatin, low-dose paclitaxel 190
Cisplatin, etoposide 193 193 12 193 32
Gatzemeier26 Cisplatin, paclitaxel 207 190 26 207 30
Cisplatin 207 197 17 207 36
Sandler27 Cisplatin, gemcitabine 260 245 32 260 39
Cisplatin 262 240 12 262 28
Gebbia28 Cisplatin, vinorelbine 122 122 39 122 15
Cisplatin, vindesine, mitomycin 125 125 42 125 15
Negoro*19 Cisplatin, irinotecan 133 126 44 129 47
Cisplatin, vindesine 133 120 32 122 38
Kubota29 Cisplatin, docetaxel 151 151 37 151 48
Cisplatin, vindesine 151 151 21 151 41
a Patients randomized; b patients eligible after randomization; c patients in the high-dose and low-dose paclitaxel groups combined. 3G, third generation;
2G, second generation; RCT, randomized controlled trials. *The relevant data from two, three-arm trials were extracted and used in the comparison of 3G
platinum-based versus 2G platinum-based regimens. Data are not shown for the treatment arm of single-agent vinorelbine in the trial by Le Chevalier et al.16
or for the treatment arm of single irinotecan in the trial by Negoro et al.19
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considered an acceptable comparator arm at the time these
trials were performed. A meta-analysis from 52 trials that
enrolled 9837 patients, published in 1995, determined that
cisplatin-based chemotherapy produced a 10% improvement
in 1-year survival over BSC.35 Because two thirds of the
cisplatin-based regimens included a vinca alkaloid or etopo-
side, it could not be determined whether cisplatin, the other
drugs, or both were responsible for the improvement in
survival. The meta-analysis by Lilenbaum et al.34 found that
treatment with single-agent platinum analogue had a similar
survival to combination therapy as well. A randomized trial
of cisplatin versus cisplatin and etoposide demonstrated
equivalent response rates and survival between the two treat-
ments.36 These data suggest that single-agent cisplatin is not
a significantly inferior therapy to other 2G regimens.
Treatment with 3G combination therapy resulted in an
improvement in the efficacy parameter of response in com-
parison to 2G platinum-based regimens. Because of concerns
about the heterogeneity of the trials, a summary RD could not
be estimated reliably on the basis of a p value of 0.06 on the
test for homogeneity. A similar meta-analysis by Le Cheva-
lier et al.37 compared gemacitabine and, in combination with
platinum agent versus first-generation and 2G platinum-based
comparator regimens, found significant heterogeneity
(p0.032) as well. The estimated RD for 1-year survival for
this comparison was 5% (95% CI: 2%, 8%), corresponding to
an NNT of 20 for one additional patient to survive 1 year after
diagnosis. These estimates should not be considered defini-
tive evidence of a survival advantage for 3G combination
therapies over 2G platinum-based regimens but, rather, as
hypothesis generating.
The use of publication-based data rather than individual
patient data may have limited the ability to explore the
contributions of specific patient characteristics to the hetero-
geneity. It is possible that there were significant differences in
the percentage of patients receiving second-line therapies
among the trials, resulting in differences in overall survival.
For instance, the trial by Gatzemeier et al.26 compared a 2G
regimen cisplatin (100 mg/m2) against a 3G regimen of
cisplatin (80 mg/m2) and paclitaxel (175 mg/m2) every three
weeks. The 3G regimen had a significantly higher response
rate (26% versus 17%, respectively; p  0.028), but there
were no statistically significant differences in median time to
tumor progression (4.1 versus 2.7 months; respectively; p 
0.26) or median survival (8.1 versus 8.6 months, respectively;
p  0.826). More patients on the cisplatin arm received
second-line therapy.
The inclusion of single-, double-, and triple-agent ther-
apies into the broad classification of 2G regimens seems to
have contributed to the heterogeneity as well. Within the
category of 2G regimens three trials used single-agent cis-
platin, six trials used cisplatin in combination with a second
agent, and three trials used three-agent therapy. When view-
ing these trials in aggregate, there is significant heterogeneity.
Nevertheless, a subgroup analysis demonstrates excellent
homogeneity of results in the individual comparisons of 3G
regimens to 2G doublets and 3G regimens compared with 2G
triplets. A summary statistic could not reasonably be gener-
ated for the comparison of 3G regimens with 2G single
agents, because of considerable heterogeneity (p 0.001). In
contrast, excellent consistency of study results was observed
among the six trials comparing 3G regimens against 2G
doublets (homogeneity p value  0.93). This comparison
reveals a 1-year overall survival RD of 6% (95% CI: 2%,
10%), favoring 3G regimens over 2G doublets (Figure 6).
Excellent consistency was also observed among the three
trials comparing 3G regimens against 2G triplet combinations
(homogeneity p value  0.91). Nevertheless, an RD of 0%
(95% CI: 7%, 6%) indicates no difference in the estimated
1-year overall survival between 3G regimens and 2G triplets.
FIGURE 5. Third-generation platinum-based regimens
compared with second-generation platinum-based regimens.
Differences in 1-year survival proportions.
FIGURE 4. Third-generation platinum-based regimens
compared with second-generation platinum based regimens.
Differences in response proportions.
Journal of Thoracic Oncology • Volume 2, Number 9, September 2007 Third-Generation Chemotherapy Agents for NSCLC
Copyright © 2007 by the International Association for the Study of Lung Cancer 851
Several other studies have investigated the efficacy of
3G agents. A previous systematic review revealed an im-
provement in survival for treatment with cisplatin and a 3G
agent (defined as gemcitabine, paclitaxel, irinotecan, and
vinorelbine) versus treatment with cisplatin and a 2G agent.33
A meta-analysis by Le Chevalier et al.37 that specifically
investigated the efficacy of the 3G agent gemcitabine found
an improvement in progression-free survival and overall
survival for treatment with platinum-based therapy with gem-
citabine, over 2G platinum-based combinations. A second
meta-analysis of eight trials (2425 patients) compared treat-
ment with cisplatin and a 3G agent (defined as taxanes,
vinorelbine, gemcitabine, and irinotecan) against treatment
with cisplatin and a 2G agent (defined as vindesine, etopo-
side, teniposide, mitomycin C, and ifosfamide), revealing
superior response and survival with cisplatin and a 3G
agent.38 These studies indicate that the 3G agents have been
a significant advance in the treatment of NSCLC.
There are several weaknesses of this meta-analysis. We
did not investigate differences in the rate and severity of treat-
ment-related toxicity or quality of life between treatment with
3G agents and previous therapies. Rather, the goal of this
meta-analysis was to assess the impact of 3G on efficacy
parameters. A separate meta-analysis evaluating these issues
would be a valuable addition to the literature. Another limitation
is the potential influence of publication bias. Although the two
tests that were conducted to address this issue produced little or
no evidence of publication bias, the small number of trials
limited the power of these tests. The strengths of this meta-
analysis are that it specifically evaluates three different clinical
scenarios, and two frequently used efficacy endpoints.
The use of response as an endpoint is open to question
because differences in response between two treatments may
not translate into differences in survival. For instance, for the
comparison of 3G monotherapy versus 2G platinum-based
regimens, the response comparison suggested a higher re-
sponse rate for 2G platinum-based therapy, but the 1-year
survival rate was equivalent between 3G monotherapy and
the 2G platinum-based regimens; this strongly supports that
these agents have improved therapy for the treatment of
advanced NSCLC. Nevertheless, response rate is frequently
used as an efficacy endpoint for many phase II trials evalu-
ating new agents or combinations, and the estimation of the
response rate with previous regimens from a meta-analysis
may assist in the development of future clinical trials.
There is currently no standard chemotherapy combina-
tion for advanced NSCLC, and the American Society of
Clinical Oncology guidelines recommend treatment with
double-agent chemotherapy for patients with advanced dis-
ease and good functional status.5 The standard therapy for
many physicians and oncology cooperative groups is a 3G
agent in combination with a cisplatin or carboplatin. Never-
theless, there has been development of several “targeted”
therapies, multitargeted tyrosine kinase inhibitors, and new
cytotoxic chemotherapy agents that have shown activity in
advanced NSCLC since the development of the 3G agents.
Bevacizumab in combination with carboplatin and paclitaxel
has demonstrated an improvement in survival in a select
group of first-line patients.39 In the second-line setting, erlo-
tinib (an epidermal growth factor receptor tyrosine kinase
inhibitor) and pemetrexed (a multitargeted antifolate) have
demonstrated activity in patients who have progressed after
first-line therapy as well in phase III trials.40,41 The multitar-
geted tyrosine kinase inhibitors (suntinib, sorafenib, ZD6474)
have demonstrated activity in phase II trials in patients
experiencing progression after first-line therapy.42–44 Many
of these new agents have been or will be integrated into 3G
combination therapies for patients with preserved functional
status, or they may be integrated with single 3G agents for
elderly patients or those with marginal functional status.
Thus, 3G agents will continue to have a major role in the
treatment of advanced NSCLC.
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